What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Deep learning has achieved remarkable success in numerous domains with help from large amounts of big data. However, the quality of data labels is a concern because of the lack of high-quality labels ...

Berlin: Bayer has received approval from the European Commission (EC) for a label extension in the European Union (EU) for ...

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME: Berlin Saturday, June 28, 2025, 09:00 Hrs [IST] The Eur ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company ...

Dear Heloise: If you want to remove the commercial label from an empty plastic container, don’t fuss with soaking the container in soapy water and trying to scrape it off. A thin coat of peanut ...

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...